A placebo-controlled trial of mirtazapine for the management of methamphetamine withdrawal

References

• Hando J, Topp L, Hall W. Amphetamine-related harms and treatment preferences of regular amphetamine users in Sydney, Australia. Drug Alcohol Depend 1997; 46: 105–113
   PubMed Web of Science ®Google Scholar
• Vincent N, Shoobridge J, Ask A, Allsop S, Ali R. Physical and mental health problems in amphetamine users from metropolitan Adelaide, Australia. Drug Alcohol Rev 1998; 17: 187–195
   PubMed Web of Science ®Google Scholar
• Zweben J E, Cohen J B, Christian D, et al. Psychiatric symptoms in methamphetamine users. Am J Addict 2004; 13: 181–190
   PubMed Web of Science ®Google Scholar
• Dyer K R, Cruickshank C C. Depression and other psychological health problems among methamphetamine dependent patients in treatment: implications for assessment and treatment outcome. Aust Psychol 2005; 40: 95–107
   Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th edition, text revision. American Psychiatric Association, Washington, DC 2000
   Google Scholar
• Topp L, Mattick R P. Validation of the amphetamine dependence syndrome and the SAmDQ. Addiction 1997; 92: 151–162
   PubMed Web of Science ®Google Scholar
• Cantwell B, McBride A J. Self detoxification by amphetamine dependent patients: a pilot study. Drug Alcohol Depend 1998; 49: 157–163
   PubMed Web of Science ®Google Scholar
• Gossop M R, Bradley B P, Brewis R K. Amphetamine withdrawal and sleep disturbance. Drug Alcohol Depend 1982; 10: 177–183
   PubMed Web of Science ®Google Scholar
• McGregor C, Srisurapanont M, Jittiwutikarn J, Laobhripatr S, Wongtan T, White J M. The nature, time course and severity of methamphetamine withdrawal. Addiction 2005; 100: 1320–1329
   PubMed Web of Science ®Google Scholar
• Oswald I, Thacore V R. Amphetamine and phenmetrazine addiction: abnormalities in the abstinence syndrome. BMJ 1963; 2: 427–431
   PubMedGoogle Scholar
• Srisurapanont M, Jarusuraisin N, Jittiwutikan J. Amphetamine withdrawal: I. Reliability, validity and factor structure of a measure. Aust NZ J Psychiatry 1999; 33: 89–93
   PubMed Web of Science ®Google Scholar
• Watson R, Hartmann E, Schildkraut J J. Amphetamine withdrawal: affective state, sleep patterns, and MHPG excretion. Am J Psychiatry 1972; 129: 263–269
   PubMed Web of Science ®Google Scholar
• Johanson C E, Frey K A, Lundahl L H, et al. Cognitive function and nigrostriatal markers in abstinent methamphetamine abusers. Psychopharmacology (Berl) 2006; 185: 327–338
   PubMed Web of Science ®Google Scholar
• Nordahl T E, Salo R, Natsuaki Y, et al. Methamphetamine users in sustained abstinence: a proton magnetic resonance spectroscopy study. Arch Gen Psychiatry 2005; 62: 444–452
   PubMed Web of Science ®Google Scholar
• Sekine Y, Iyo M, Ouchi Y, et al. Methamphetamine-related psychiatric symptoms and reduced brain dopamine transporters studied with PET. Am J Psychiatry 2001; 158: 1206–1214
   PubMed Web of Science ®Google Scholar
• Sekine Y, Minabe Y, Ouchi Y, et al. Association of dopamine transporter loss in the orbitofrontal and dorsolateral prefrontal cortices with methamphetamine-related psychiatric symptoms. Am J Psychiatry 2003; 160: 1699–1701
   PubMed Web of Science ®Google Scholar
• Volkow N D, Chang L, Wang G J, et al. Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am J Psychiatry 2001; 158: 377–382
   PubMed Web of Science ®Google Scholar
• Lingford-Hughes A R, Welch S, Nutt D J. Evidence-based guidelines for the pharmacological management of substance misuse, addiction and comorbidity: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2004; 18: 293–335
   PubMed Web of Science ®Google Scholar
• Srisurapanont M, Jarusuraisin N, Kittirattanapaiboon P. Treatment for amphetamine withdrawal. Cochrane Database Syst Rev 2002; 4, CD003021
   Google Scholar
• Johnson B A, Ait-Daoud N, Elkashef A M, et al. A preliminary randomized, double-blind, placebo-controlled study of the safety and efficacy of ondansetron in the treatment of methamphetamine dependence. Int J Neuropsychopharmacol 2007; 1: 1–14
   Google Scholar
• Heinzerling K G, Shoptaw S, Peck J A, et al. Randomized, placebo-controlled trial of baclofen and gabapentin for the treatment of methamphetamine dependence. Drug Alcohol Depend 2006; 85: 177–184
   PubMed Web of Science ®Google Scholar
• Tiihonen J, Kuoppasalmi K, Fohr J, et al. A comparison of aripiprazole, methylphenidate, and placebo for amphetamine dependence. Am J Psychiatry 2007; 164: 160–162
   PubMed Web of Science ®Google Scholar
• Shoptaw S, Huber A, Peck J, et al. Randomized, placebo-controlled trial of sertraline and contingency management for the treatment of methamphetamine dependence. Drug Alcohol Depend 2006; 85: 12–18
   PubMed Web of Science ®Google Scholar
• Elkashef A M, Rawson R A, Anderson A L, et al. Bupropion for the treatment of methamphetamine dependence. Neuropsychopharmacology 2007, Epub 20 June 2007. doi:10.1038/sj.npp.1301481
   PubMedGoogle Scholar
• White R. Dexamphetamine substitution in the treatment of amphetamine abuse: an initial investigation. Addiction 2000; 95: 229–238
   PubMed Web of Science ®Google Scholar
• Shearer J, Wodak A, Mattick R P, et al. Pilot randomized controlled study of dexamphetamine substitution for amphetamine dependence. Addiction 2001; 96: 1289–1296
   PubMed Web of Science ®Google Scholar
• Anttila S A, Leinonen E V. A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev 2001; 7: 249–264
   PubMedGoogle Scholar
• Ruigt G S, Kemp B, Groenhout C M, Kamphuisen H A. Effect of the antidepressant Org 3770 on human sleep. Eur J Clin Pharmacol 1990; 38: 551–554
   PubMed Web of Science ®Google Scholar
• Kongsakon R, Papadopoulos K I, Saguansiritham R. Mirtazapine in amphetamine detoxification: a placebo-controlled pilot study. Int Clin Psychopharmacol 2005; 20: 253–256
   PubMed Web of Science ®Google Scholar
• McGregor C. Amphetamine withdrawal: nature, time course and treatment [dissertation]. South Australia: The University of Adelaide, Adelaide 2005
   Google Scholar
• MIMS Online. Crows Nest, New South Wales: Monthly Index of Medical Specialties Australia; c2005 [cited 1 February 2005]. Available at: http://mims.hcn.net.au (accessed 1 February 2005).
   Google Scholar
• Dallal GE. Randomization.com. [updated 10 April 2003; cited 14 January 2005]. Available at: http://www.randomization.com (accessed 14 January 2005).
   Google Scholar
• France C M, Uhlin B D. Narrative as an outcome domain in psychosis. Psychol Psychother 2006; 79: 53–67
   PubMed Web of Science ®Google Scholar
• McGregor C, Srisurapanont M, Mitchell A, Longo M, Cahill S, White J M. Psychometric evaluation of the Amphetamine Cessation Symptom Assessment (ACSA). J Subst Abuse Treat, Epub 13 July 2007. doi:10.1016/j.jsat.2007.05.007
   Google Scholar
• Soldatos C R, Dikeos D G, Paparrigopoulos T J. Athens Insomnia Scale: validation of an instrument based on ICD-10 criteria. J Psychosom Res 2000; 48: 555–560
   PubMed Web of Science ®Google Scholar
• Derogatis L R. Brief symptom inventory administration, scoring, and procedures manual. The Psychological Corporation, National Computer Systems, Inc., Minneapolis 1993
   Google Scholar
• Lovibond P F, Lovibond S H. The structure of negative emotional states: comparison of the Depression Anxiety Stress Scales (DASS) with the Beck Depression and Anxiety Inventories. Behav Res Ther 1995; 33: 335–343
   PubMed Web of Science ®Google Scholar
• Gossop M, Darke S, Griffiths P, et al. The Severity of Dependence Scale (SDS): psychometric properties of the SDS in English and Australian samples of heroin, cocaine and amphetamine users. Addiction 1995; 90: 607–614
   PubMed Web of Science ®Google Scholar
• Darke S, Ward J, Hall W, Heather N, Wodak A. The Opiate Treatment Index (OTI) researcher's manual. National Drug and Alcohol Research Centre Technical Report no. 11. National Drug and Alcohol Research Centre, Sydney, New South Wales 1991
   Google Scholar
• Soldatos C R, Dikeos D G, Paparrigopoulos T J. The diagnostic validity of the Athens Insomnia Scale. J Psychosom Res 2003; 55: 263–267
   PubMed Web of Science ®Google Scholar
• Derogatis L R, Melisaratos N. The Brief Symptom Inventory: an introductory report. Psychol Med 1983; 13: 595–605
   PubMed Web of Science ®Google Scholar
• Antony M M, Bieling P J, Cox B J, Enns M W, Swinson R P. Psychometric properties of the 42-item and 21-item versions of the depression anxiety stress scales in clinical groups and a community sample. Psychol Assess 1998; 10: 176–181
   Web of Science ®Google Scholar
• Topp L, Mattick R P. Choosing a cut-off on the Severity of Dependence Scale (SDS) for amphetamine users. Addiction 1997; 92: 839–845
   PubMed Web of Science ®Google Scholar
• Friedman H. Simplified determinations of statistical power, magnitude of effect and research sample sizes. Educ Psychol Meas 1982; 42: 521–526
   Web of Science ®Google Scholar
• Muehlbacher M, Nickel M K, Nickel C, et al. Mirtazapine treatment of social phobia in women: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 2005; 25: 580–583
   PubMed Web of Science ®Google Scholar
• Thompson C. Mirtazapine versus selective serotonin reuptake inhibitors. J Clin Psychiatry 1999; 60(Suppl 17)18–22
   PubMedGoogle Scholar
• Aharonovich E, Nunes E, Hasin D. Cognitive impairment, retention and abstinence among cocaine abusers in cognitive – behavioral treatment. Drug Alcohol Depend 2003; 71: 207–211
   PubMed Web of Science ®Google Scholar
• Baker A, Lee N K, Claire M, et al. Brief cognitive behavioural interventions for regular amphetamine users: a step in the right direction. Addiction 2005; 100: 367–378
   PubMed Web of Science ®Google Scholar
• Rawson R A, Marinelli-Casey P, Anglin M D, et al. A multi-site comparison of psychosocial approaches for the treatment of methamphetamine dependence. Addiction 2004; 99: 708–717
   PubMed Web of Science ®Google Scholar